Published by
@ShahidNShah
@ShahidNShah
October 30 to November 1, 2023
Hilton Boston Logan Airport, One Hotel Dr, Boston, Massachusetts, 02128, United States
The HER2 field remains dynamic with the success of Enhertu and Herceptin. In 2023, attention is shifting to non-breast cancer types, where Anti-HER2 therapies are making significant progress. Beyond ADCs, multispecific antibodies, cell therapy, and radiopharmaceuticals are delivering promising outcomes for various cancer types. This comprehensive conference addresses HER2 challenges in breast cancer and non-breast tumors, facilitating the development of diverse therapeutics. The goal is to expand the clinical utility of HER2 as a multi-tumor target, transcending the boundaries of breast cancer.
Continue reading at her2-targeted-therapies.com
October 30 to October 31, 2023
20-22 Wenlock Rd, London N1 7Guildford, United Kingdom
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Media LLC. All Rights Reserved.
Built on Apr 26, 2024 at 6:14am